Qiagen launches companion test for Novartis breast cancer treatment

Dive Brief:

  • Qiagen said it has launched the first FDA-approved companion diagnostic for identifying breast cancer patients who may benefit from treatment with Novartis’ Piqray (alpelisib).
  • Novartis last week announced FDA approval of the kinase inhibitor designed specifically for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative​ advanced breast cancer patients with a PIK3CA mutation.
  • Qiagen said it has a worldwide co-exclusive license from Johns Hopkins University for PCR-based companion diagnostics based on mutations in the PIK3CA gene.

Click here to read more via Med Tech Drive.

Join our Mailing List